Shield Therapeutics (STX) Share Price, News & Analysis

Company Overview

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc. (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies. Feraccru® is commercialized in the UK and European Union by Norgine B.V. (Norgine), which also has marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of Accrufer®/ Feraccru® in China, Hong Kong, Macau and Taiwan; with Korea Pharma Co., Ltd. for the Republic of Korea (Korea Pharma); and with KYE Pharmaceuticals Inc. for Canada. Accrufer®/Feraccru® has patent coverage until the mid-2030s. Accrufer®/Feraccru® are registered trademarks of Shield Therapeutics.

Key Stats

• Today's Range: 2.20 to 2.60
• 50-Day Range: 2.26 to 3.59
• 52-Week Range: 1.40 to 5.87
• Volume: 3.44 million shs
• Average Volume: 2.54 million shs
• Market Capitalization: £24.67 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

STX Stock Analysis - Frequently Asked Questions

How have STX shares performed this year?

Shield Therapeutics' stock was trading at GBX 2.70 on January 1st, 2025. Since then, STX stock has decreased by 7.4% and is now trading at GBX 2.50.
View the best growth stocks for 2025 here.

How were Shield Therapeutics' earnings last quarter?

Shield Therapeutics plc (LON:STX) posted its earnings results on Thursday, April, 24th. The company reported ($3.00) earnings per share (EPS) for the quarter. Shield Therapeutics had a negative net margin of 173.43% and a negative trailing twelve-month return on equity of 470.50%.

How do I buy shares of Shield Therapeutics?

Shares of STX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Shield Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Shield Therapeutics investors own include AcelRx Pharmaceuticals (ACRX), Rockwell Medical (RMTI), AstraZeneca (AZN), Model N (MODN), Cara Therapeutics (CARA), Caladrius Biosciences (CLBS) and Cellectis (CLLS).

Company Calendar

• Last Earnings: 4/24/2025
• Today: 5/02/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: Computer Hardware
• Current Symbol: LON:STX
• CIK: N/A
• Web: www.shieldtherapeutics.com
• Phone: +44-191-5118500
• Fax: N/A
• Employees: 40,000
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (3.88)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 33.92
• P/E Growth: N/A
• Net Income: £-36,277,039.98
• Net Margins: -173.43%
• Pretax Margin: N/A
• Return on Equity: -470.50%
• Return on Assets: -47.85%

Debt

• Debt-to-Equity Ratio: 3,691.50
• Current Ratio: 1.05
• Quick Ratio: 2.16

Sales & Book Value

• Annual Sales: £20.92 million
• Price / Sales: 1.13
• Cash Flow: GBX 0.38 per share
• Price / Cash Flow: 6.36
• Book Value: GBX 0.05 per share
• Price / Book: 43.86

Miscellaneous

• Outstanding Shares: 986,864,211
• Free Float: N/A
• Market Cap: £23.68 million
• Optionable: Not Optionable
• Beta: 1.42